Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Low-Dose Versus Standard-Dose Tenecteplase for Acute Minor Ischemic Stroke With Disabling Deficits (MILD-EFFECT)

17 november 2026 bijgewerkt door: Shandong Provincial Hospital

Low-Dose Recombinant Human Tenecteplase Tissue-Type Plasminogen Activator for Injection in Acute Minor Ischemic Stroke With Disabling Deficits: The MILD-EFFECT Multicenter Randomized Controlled Trial

This study will compare two doses of a clot-dissolving medicine called tenecteplase (TNK), specifically recombinant human TNK tissue-type plasminogen activator for injection (rhTNK-tPA), in adults with a mild ischemic stroke that causes disabling symptoms. An ischemic stroke occurs when a blood clot blocks blood flow to the brain. Even a mild stroke can cause problems that prevent a person from carrying out basic daily activities or returning to work.

The main question is whether a lower dose of rhTNK-tPA helps patients recover nearly as well as the standard dose, within a predefined acceptable difference. The study will also compare bleeding and other side effects between the two doses.

Up to 1,324 participants at multiple hospitals will be randomly assigned to receive either the lower dose (0.18 mg/kg, up to 16 mg) or the standard dose (0.25 mg/kg, up to 25 mg). Each participant will receive one injection into a vein within 4.5 hours of stroke onset, along with usual stroke care. Participants and treating doctors will know which dose is given, but the assessors evaluating recovery will not.

Participants will be followed for approximately 90 days. Researchers will assess recovery, ability to carry out daily activities, quality of life, bleeding, and other medical problems. The main outcome is the proportion of participants who have no symptoms or no significant disability at about 90 days after treatment.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

1324

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: QinJian Sun
  • Telefoonnummer: 86-0531-68773275
  • E-mail: sqj1210@163.com

Studie Locaties

    • Shandong
      • Jinan, Shandong, China, 250021
        • Werving
        • Shandong Provincial Hospital Affiliated to Shandong First Medical University
        • Contact:
          • Qinjian Sun, MD
          • Telefoonnummer: +86-0531-68773275
          • E-mail: sqj1210@163.com
        • Hoofdonderzoeker:
          • QinJian Sun

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Age ≥18 years.
  2. Clinical diagnosis of acute ischemic stroke with a baseline National Institutes of Health Stroke Scale (NIHSS) score ≤5.
  3. Presence of clearly disabling neurological deficits that persist and prevent the participant from independently performing at least one basic activity of daily living (including bathing, dressing, walking, toileting, personal hygiene, and eating) and/or returning to their previous work.
  4. Time from stroke onset to treatment <4.5 hours, with onset defined as the time of symptom onset or the last known well time.
  5. Pre-stroke modified Rankin Scale (mRS) score ≤1.
  6. Voluntary participation and written informed consent provided by the participant or their legally authorized representative.

Exclusion Criteria:

  1. Intracranial hemorrhage, including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural hematoma, or epidural hematoma.
  2. NIHSS item 1a score >2.
  3. Planned endovascular treatment before randomization.
  4. History of intracranial hemorrhage, or presence of an intra-axial intracranial tumor, giant intracranial aneurysm, or arteriovenous malformation.
  5. History of stroke within the preceding 3 months.
  6. Recent anticoagulant treatment with coagulation parameters that do not meet the safety requirements for thrombolysis.
  7. Active internal bleeding or an acute bleeding tendency, including a platelet count <100 × 10⁹/L.
  8. Concomitant bacterial endocarditis, pericarditis, acute pancreatitis, or other severe, difficult-to-control infections.
  9. History of major trauma (e.g., severe head injury within the preceding 3 months), surgery or invasive procedures (e.g., intracranial or spinal canal surgery within the preceding 3 months, major surgery within the preceding 2 weeks, or arterial puncture at a site not amenable to compression within the preceding week), or bleeding (e.g., gastrointestinal or urinary tract bleeding within the preceding 3 weeks).
  10. Persistent uncontrolled hypertension despite active antihypertensive treatment: systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥100 mmHg.
  11. Blood glucose <2.8 mmol/L or >22.22 mmol/L. Eligibility may be reassessed after correction of blood glucose if clearly disabling neurological deficits associated with minor stroke persist and the participant meets the diagnostic criteria for acute ischemic stroke and the eligibility requirements for intravenous thrombolysis.
  12. Postictal paresis (Todd's paresis), or other neurological or psychiatric conditions resulting in inability or unwillingness to cooperate.
  13. Known allergy to the active ingredient rhTNK-tPA or any of its excipients.
  14. Current participation in another interventional medical device or drug study, or completion of participation in such a study less than 30 days previously.
  15. Pregnancy, breastfeeding, or unwillingness of a female participant to use effective contraception during the trial.
  16. Other serious diseases associated with a life expectancy of less than 6 months.
  17. Any other condition that, in the investigator's judgment, may substantially increase bleeding risk, interfere with study assessments, or render the participant unsuitable for the trial.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Low-Dose Tenecteplase (rhTNK-tPA)

Participants will receive rhTNK-tPA at 0.18 mg/kg, with a maximum dose of 16 mg, administered as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines.

Tenecteplase (rhTNK-tPA) will be administered at 0.18 mg/kg, with a maximum dose of 16 mg, as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines.

Andere namen:
  • rhTNK-tPA
  • Recombinant Human TNK Tissue-Type Plasminogen Activator for Injection
Actieve vergelijker: Standard-Dose Tenecteplase (rhTNK-tPA)

Participants will receive rhTNK-tPA at 0.25 mg/kg, with a maximum dose of 25 mg, administered as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines.

Tenecteplase (rhTNK-tPA) will be administered at 0.25 mg/kg, with a maximum dose of 25 mg, as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines.

Andere namen:
  • rhTNK-tPA
  • Recombinant Human TNK Tissue-Type Plasminogen Activator for Injection

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Proportion of Participants With a Modified Rankin Scale (mRS) Score of 0-1
Tijdsspanne: 90 ± 7 days after randomization

The modified Rankin Scale (mRS) measures functional disability after stroke. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating worse outcomes. An mRS score of 0-1 indicates no significant disability.

90 ± 7 days after randomization

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Proportion of Participants With a Modified Rankin Scale (mRS) Score of 0-2
Tijdsspanne: 90 ± 7 days after randomization

The modified Rankin Scale (mRS) measures functional disability after stroke. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating worse outcomes. An mRS score of 0-2 indicates functional independence.

90 ± 7 days after randomization
Distribution of Modified Rankin Scale (mRS) Scores
Tijdsspanne: 90 ± 7 days after randomization

The modified Rankin Scale (mRS) measures functional disability after stroke. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating worse outcomes. The distribution across all seven categories (0-6) will be assessed.

90 ± 7 days after randomization
Proportion of Participants With a National Institutes of Health Stroke Scale (NIHSS) Score of 0-1
Tijdsspanne: 22-36 hours after randomization and at day 7 ± 1 or discharge, whichever occurs first

The National Institutes of Health Stroke Scale (NIHSS) assesses neurological deficits after stroke. Total scores range from 0 to 42, with higher scores indicating greater neurological impairment. An NIHSS score of 0-1 indicates no or minimal neurological deficits.

22-36 hours after randomization and at day 7 ± 1 or discharge, whichever occurs first
Proportion of Participants With an Increase From Baseline of ≥2 Points in Total NIHSS Score or ≥1 Point in Any Motor Item Score
Tijdsspanne: Baseline to 22-36 hours after randomization and to day 7 ± 1 or discharge, whichever occurs first

The National Institutes of Health Stroke Scale (NIHSS) assesses neurological deficits after stroke. Total scores range from 0 to 42, with higher scores indicating greater neurological impairment. Each motor item is scored from 0 to 4. Neurological worsening is defined as an increase of ≥2 points in the total NIHSS score or ≥1 point in any motor item compared with baseline.

Baseline to 22-36 hours after randomization and to day 7 ± 1 or discharge, whichever occurs first
Proportion of Participants With a Decrease From Baseline of ≥2 Points in Total NIHSS Score or ≥1 Point in Any Motor Item Score
Tijdsspanne: Baseline to 22-36 hours after randomization and to day 7 ± 1 or discharge, whichever occurs first

The National Institutes of Health Stroke Scale (NIHSS) assesses neurological deficits after stroke. Total scores range from 0 to 42, with higher scores indicating greater neurological impairment. Each motor item is scored from 0 to 4. Neurological improvement is defined as a decrease of ≥2 points in the total NIHSS score or ≥1 point in any motor item compared with baseline.

Baseline to 22-36 hours after randomization and to day 7 ± 1 or discharge, whichever occurs first
Proportion of Participants With a COSMOS score Grade of 0-1
Tijdsspanne: 90 ± 7 days after randomization

The Canadian Outcome Scale for Minor Stroke (COSMOS) assesses functional outcomes after minor stroke, including limitations in daily activities and participation in meaningful activities. Scores range from 0 (no symptoms) to 6 (loss of independence or worse), with higher scores indicating worse outcomes. The proportion of participants with a COSMOS grade of 0-1 will be assessed.

90 ± 7 days after randomization
COSMOS Score
Tijdsspanne: 90 ± 7 days after randomization

The Canadian Outcome Scale for Minor Stroke (COSMOS) assesses functional outcomes after minor stroke, including limitations in daily activities and participation in meaningful activities. Scores range from 0 (no symptoms) to 6 (loss of independence for an instrumental or basic activity of daily living or worse), with higher scores indicating worse outcomes. The distribution of COSMOS grades from 0 to 6 at 90 days will be assessed.

90 ± 7 days after randomization
Health-Related Quality of Life Assessed by EQ-5D-3L and EQ VAS
Tijdsspanne: 90 ± 7 days after randomization

The EuroQol Five-Dimension Three-Level Questionnaire (EQ-5D-3L) assesses health-related quality of life across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has three response levels, ranging from 1 (no problems) to 3 (extreme problems or inability to perform the activity), with higher levels indicating worse health status. The accompanying EuroQol Visual Analogue Scale (EQ VAS) assesses self-rated overall health on a scale from 0 (worst imaginable health) to 100 (best imaginable health), with higher scores indicating better health status.

90 ± 7 days after randomization
Incidence of Symptomatic Intracranial Hemorrhage According to ECASS III Criteria Within 36 Hours
Tijdsspanne: Within 36 hours after study drug administration

Symptomatic intracranial hemorrhage (sICH) is defined according to the European Cooperative Acute Stroke Study III (ECASS III) criteria as any intracranial hemorrhage associated with neurological deterioration, defined as an increase of ≥4 points in the National Institutes of Health Stroke Scale (NIHSS) score, or resulting in death, with the hemorrhage identified as the predominant cause of neurological deterioration or death.

Within 36 hours after study drug administration
Incidence of Any Intracranial Hemorrhage Within 36 Hours
Tijdsspanne: Within 36 hours after study drug administration

Any intracranial hemorrhage is defined as the presence of intracranial bleeding detected by brain computed tomography (CT) or magnetic resonance imaging (MRI), regardless of whether neurological deterioration or clinical symptoms are present. Both symptomatic and asymptomatic intracranial hemorrhages are included.

Within 36 hours after study drug administration
Incidence of Symptomatic Intracranial Hemorrhage According to ECASS III Criteria Within 7 Days
Tijdsspanne: Within 7 days after study drug administration

Symptomatic intracranial hemorrhage (sICH) is defined according to the European Cooperative Acute Stroke Study III (ECASS III) criteria as any intracranial hemorrhage associated with neurological deterioration, defined as an increase of ≥4 points in the National Institutes of Health Stroke Scale (NIHSS) score, or resulting in death, with the hemorrhage identified as the predominant cause of neurological deterioration or death. Events occurring within 7 days after study drug administration will be assessed.

Within 7 days after study drug administration
Incidence of Major Extracranial Bleeding According to ISTH Criteria
Tijdsspanne: Within 7 days after study drug administration

Major extracranial bleeding is defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria as bleeding outside the cranium meeting at least one of the following: fatal bleeding; symptomatic bleeding in a critical extracranial area or organ, including intraspinal, intraocular, retroperitoneal, intra-articular, or pericardial bleeding, or intramuscular bleeding with compartment syndrome; a decrease in hemoglobin of ≥2 g/dL; or transfusion of ≥2 units of whole blood or red blood cells.

Within 7 days after study drug administration
Proportion of Participants With a Modified Rankin Scale (mRS) Score of 5-6
Tijdsspanne: 90 ± 7 days after randomization

The modified Rankin Scale (mRS) measures functional disability after stroke. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating worse outcomes. An mRS score of 5-6 indicates severe disability or death.

90 ± 7 days after randomization
All-Cause Mortality
Tijdsspanne: Within 90 days after randomization
Within 90 days after randomization
Proportion of Participants Experiencing at Least One Adverse Event
Tijdsspanne: Within 90 days after study drug administration
Within 90 days after study drug administration
Proportion of Participants Experiencing at Least One Serious Adverse Event
Tijdsspanne: Within 90 days after study drug administration
Within 90 days after study drug administration

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: QinJian Sun, Shandong Provincial Hospital

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

15 oktober 2026

Primaire voltooiing (Geschat)

1 april 2029

Studie voltooiing (Geschat)

1 juli 2029

Studieregistratiedata

Eerst ingediend

29 oktober 2026

Eerst ingediend dat voldeed aan de QC-criteria

17 november 2026

Eerst geplaatst (Werkelijk)

18 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 november 2026

Laatste update ingediend die voldeed aan QC-criteria

17 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren